Atlas Trials

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Clinical trial NCT05475678 · RECRUITING

Trial details

NCT number
NCT05475678
Sponsor
Zhenzhen Liu
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerTriple Negative Breast CancerCamrelizumab
Start date
2022-12-20
Primary completion
2025-05-31
Enrollment
369

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.